Michigan Forms Rare Disease Council to Amplify Patient Voices Statewide

October 24, 2024

Michigan Launches Rare Disease Advisory Council

he Michigan Department of Health & Human Services has made appointments to a newly constituted Rare Disease Advisory Council. A rare disease is a condition that affects fewer than 200,000 people in the United States. There are more than 7,000 known rare diseases and almost 1 in 10 Michiganders suffer from a rare disorder.


The MI-RDAC will serve as an advisory body that provides Michigan’s rare disease community with a stronger voice in state government. Nationwide, 29 states have established RDACs, with others in various stages of the process. The responsibilities of the MI-RDAC include 1) providing information about rare diseases, and 2) in collaboration with MDHHS, investigating and reporting to the state legislature about rare diseases, unmet needs and other challenges accessing appropriate care and treatments. Meetings will be held quarterly, with virtual access available.


MichBio received an appointment to the 18-member MI-RDAC – see the roster of members here – a diverse set of stakeholders with backgrounds of relevance to the rare disease community. An inaugural meeting took place in early October 2024 and the RDAC plans to meet at least quarterly to develop its mission and goals.



The passage of HB 4167 with substitute language by the Michigan Senate would ensconce the MI-RDAC by statute. The bill is pending a final vote.

RECENT ARTICLES

MichBio Hiring: Intern, Association Membership & Resource Analytics

April 15, 2025
MichBio seeks a highly motivated individual who can work creatively in a small team environment and assist in data mining, compilation, and research.

Bio Survey Underscores Impacts of Tariffs for Businesses

April 11, 2025
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate recently released the results of a survey of its members, noting that “U.S. Biotechs Sound the Alarm” on tariff impacts. The findings include: Tariffs on European Union and Canadian imports would increase manufacturing costs for 94% and 82% of biotech firms, respectively. 70% of companies anticipate higher manufacturing costs due to tariffs on China. Tariffs on the European Union would force 50% of biotech firms to identify new research and manufacturing partners. More than 50% of biotech firms predict “increased difficulty” in funding and conducting research if EU tariffs are enacted. 80% of biotech firms would need at least 12 months to find alternative suppliers; 44% would need over two years. The survey noted that sudden tariffs would fundamentally punish American companies, threaten vital research projects and imperil United States leadership in biomedical science. Read BIO’s press release , along with an one-pager summarizing the survey results. 

Amid Proposed Cuts, Commission Calls For $15B NIH Support

April 10, 2025
A federal commission, in a new report , is calling for $15 billion in new financing to reinforce the United States’ biotech leadership amid encroaching competition from China. This comes against a backdrop where the Trump Administration has proposed severe cuts to NIH operations and funding. The National Security Commission on Emerging Biotechnology was created by Congress in 2022 to explore how biotechnology advancements could shape the economy and national security. The body quickly focused on China, as that government has gone about gathering Americans’ genetic information and intellectual property in the biotech space and resourcing their cluster’s rapid growth. The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework to protect U.S. biotech intellectual property and bolster drug development, agriculture, and biological weapons defense: Prioritize biotechnology at the national level Mobilize the private sector to get U.S. products to scale Maximize the benefits of biotechnology for defense Out-innovate our strategic competitors Build the biotechnology workforce of the future Mobilize the collective strengths of our allies and partners The report calls for $1 billion to create an investment fund, more than $6 billion for large-scale research challenges, and a build-up of biomanufacturing sites across the country. Also, it calls for new legislation barring companies that work with U.S. national security agencies or health agencies from using certain Chinese biotech suppliers. The commission doesn’t have the power to authorize any changes but can make recommendations and advise members of Congress. BIO issued a statement in support.